Scholars Central

Search Scholars Central

Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.

Advanced searchHide advanced search

In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:

Years

1–25 of 40 articles for P2Y12 receptor

Then save them, add them to a collection or cite them together.
  1. Research article · 2016

    Impact of the New P2Y12 Receptor Inhibitors on Mortality in STElevation Myocardial Infarction Patients with Cardiogenic Shock and / or After Cardiopulmonary Resuscitation Undergoing Percutaneous Coronary Intervention

    Cardiovascular Pharmacology: Open Access · Volume 5, Issue 1

    Background: Little is known about clinical efficacy of newer P2Y12 receptor inhibitors in ST-elevation myocardial infarction patients presenting with cardiogenic shock or after cardiopulmonary resuscitation ... study…

  2. Research article · 1 Jun 2017

    DEVELOPMENT OF A VALIDATED HPLC-PDA METHOD FOR STABILITY INDICATING STUDY OF TICAGRELOR: A NOVEL ANTI-PLATELET AGENT (P2Y12-ADP RECEPTOR BLOCKER)

    International Journal of Pharmaceutical, Chemical and Biological Sciences · Volume 7, Issue 1

    HPLC method for the estimation of direct acting and reversible P2Y12-ADP receptor blocker, Ticagrelor and its stability indicating study was developed and validated according to ICH guidelines. Stress testing

  3. Conference abstract · 21 Sep 2015

    Microglia-Neuron communication in Epilepsy

    activation of neuronal NMDA receptors, calcium influx, subsequent ATP release, and microglial response through P2Y12 receptors. In addition, we serendipitously found that extracellular Ca2+ reduction induced microglial…

  4. Conference abstract · 11 Sep 2017

    ADP TREATMENT IMPROVES WOUND HEALING IN DIABETIC MICE

    mast cells and myofi broblasts in the wound. Besides, ADP positively modulated its own receptors, VEGF and TGF-α in the wound. Th ese eff ects were only observed ... interestingly, others nucleotides did not accelerate…

  5. Editorial · 17 Jun 2019

    Cardiology-2020: The Attack on Coronary Disease: Should it be before, during or after? - Mark I.M. Noble - Department of Medicine and Therapeutics, Polwarth Building, Foresterhill, Aberdeen AB25 2ZH, University of Aberdeen, UK

    Journal of Cholesterol and Heart Disease · Volume 3, Issue 3

    confirming the inhibition of arterial thrombus growth by 5HT2A receptor antagonists. The pharmaceutical industry, however, has preferred to explore agents inhibiting platelet-rich thrombosis by antagonizing the…

  6. Editorial · 10 Sep 2018

    Cardiology-2018: The Attack on Coronary Disease: Should it be before, during or after? - Mark I.M. Noble - Department of Medicine and Therapeutics, Polwarth Building, Foresterhill, Aberdeen AB25 2ZH, University of Aberdeen, UK

    Journal of Cholesterol and Heart Disease · Volume 3, Issue 3

    confirming the inhibition of arterial thrombus growth by 5HT2A receptor antagonists. The pharmaceutical industry, however, has preferred to explore agents inhibiting platelet-rich thrombosis by antagonizing the…

  7. Review article · 2020

    Investigate the Strategy of Using Pharmacogenetics and Pharmacometabonomics to the Personalization of Ticagrelor Antiplatelet Therapy

    Systematic Reviews in Pharmacy · Volume 11, Issue 9

    Background: Ticagrelor is an oral antiplatelet agent commonly used to inhibit P2Y12 receptors that bind to it inversely. It is classified as cyclopentyltriazolopyrimidine (CPTP). Unlike prasugrel and clopidogrel…

  8. Review article · 15 Jul 2016

    Ticagrelor in the treatment of coronary artery disease patients

    Clinical Practice · Volume 9, Issue 4

    Clopidogrel is a major P2Y12 receptor blocker administered in addition to aspirin to reduce the ischemic event occurrence in a wide range of patients with arterial diseases particularly in patients ... prasugrel therapy…

  9. Research article · 2016

    Dyspnea in Post Percutaneous Transluminal Coronary Angioplasty (PTCA) Patients on Dual Antiplatelets in a Tertiary Care Hospital in South India

    Cardiovascular Pharmacology: Open Access · Volume 5, Issue 3

    Transluminal Coronary Angioplasty for Acute Coronary Syndromes, Dual Antiplatelet Therapy with Aspirin and a P2Y12 receptor inhibitor like Ticagrelor or Clopidogrel is required minimum for a period of 12 months…

  10. Review article · 2013

    Insufficient Efficiency of Prasugrel in Diabetic Patients with Acute STEMI Undergoing pPCI of Culprit Coronary Lesion and#195;and#162;and#194;and#8364;and#194;and#8220; Review of Current Knowledge

    Journal of Hematology & Thromboembolic Diseases · Volume 1, Issue 4

    treatment of acute coronary syndromes. Dual antiplatelet therapy containing aspirin and P2Y12 ADP receptor antagonist forms currently the basis in acute ST – elevation myocardial infarction (STEMI) pharmacological…

  11. Conference abstract · 7 Sep 2023

    From Genetic Screening to Patient Management

    Health Science Journal

    guidelines recommend 12 months of DAPT (dual antiplatelet therapy) with aspirin and an oral P2Y12 receptor inhibitor (preferably ticagrelor or prasugrel over clopidogrel) [1]. An alternative approach has recently been…

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels